Roopesh Kansara

Winnipeg, MB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.

Journal: Haematologica

Published: August 10, 2025

Acute heparin-induced thrombocytopenia following aortic dissection repair with platelet count recovery and anti-platelet factor 4/heparin antibody seroreversion despite ongoing device-related heparin exposure.

Acute heparin-induced thrombocytopenia following aortic dissection repair with platelet count recovery and anti-platelet factor 4/heparin antibody seroreversion despite ongoing device-related heparin exposure.

Journal: Haematologica

Published: September 10, 2020

Immunotherapy in hematologic malignancies.

Immunotherapy in hematologic malignancies.

Journal: Current oncology (Toronto, Ont.)

Published: May 06, 2020

Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.

Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.

Journal: British journal of haematology

Published: July 12, 2019

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.

Journal: Blood advances

Published: May 17, 2019

Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.

Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.

Journal: Current treatment options in oncology

Published: September 12, 2018

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 23, 2017

Diffuse large B-cell lymphoma mimicking cardiac amyloidosis.

Diffuse large B-cell lymphoma mimicking cardiac amyloidosis.

Journal: Clinical case reports

Published: February 27, 2017

Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.

Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.

Journal: Haematologica

Published: August 02, 2016

Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.

Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.

Journal: British journal of haematology

Published: July 23, 2016

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 07, 2016

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.

Journal: Blood

Published: October 30, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026